📚 Part of the OBX-319 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

---

Clinical Development Plan (OBX-319)

Document ID: PM-007
Version: 1.0
Change History: 1.0 — Initial issue.
Standard(s): Program management

Clinical Development Plan — OBX-319

Sets out the development strategy for OBX-319 (bispecific monoclonal antibody) in Systemic Lupus Erythematosus (moderate-to-severe active): the target product profile, the study OBX319-301 (Phase 3) and its role, the proposed confirmatory programme, key regulatory interactions, and the path to registration.

1. Purpose and Scope

This Clinical Development Plan (CDP) is the controlling strategic document for the OBX-319 programme conducted by Virtual Biopharma Inc. It defines the intended registrational claim, the sequence of nonclinical and clinical studies that support that claim, the clinical pharmacology and quality (Chemistry, Manufacturing, and Controls [CMC]) work packages that enable it, the health-authority interaction plan, and the criteria by which the programme is judged ready for a marketing application. The CDP is a living document: it is aligned to the Target Product Profile (TPP), it governs the design intent of the pivotal study OBX319-301, and it is the reference against which programme risks (see the Program Risk Register, PM-004) and go/no-go decisions are assessed. It is written to be internally consistent with the Clinical Overview (Module 2.5), the clinical summaries (Modules 2.7), the nonclinical overview and summaries (Modules 2.4/2.6), and the quality documentation (Modules 2.3/3).

Scope covers the moderate-to-severe active Systemic Lupus Erythematosus (SLE) indication in adults on background standard of care. It encompasses the modality-specific strategy for a humanized IgG1 anti-CD19 × anti-CD20 bispecific B-cell–depleting monoclonal antibody produced in Chinese Hamster Ovary (CHO) cell culture and administered subcutaneously. Paediatric, lifecycle, and additional-population development are addressed as forward-looking work streams and are not part of the initial registrational package.

2. Target Product Profile (TPP)

The TPP anchors development decisions and is the yardstick for success. It expresses the desired registrational label and the minimally acceptable position at each attribute.

Attribute	Target (aspirational)	Minimally acceptable
Indication	Moderate-to-severe active SLE in adults inadequately controlled on standard of care	Same, with defined disease-activity entry criteria
Mechanism	Dual B-lineage depletion via simultaneous CD20 and CD19 engagement	Clinically meaningful, mechanistically corroborated B-cell depletion
Modality / route	Humanized IgG1 bispecific mAb, subcutaneous, outpatient administration	Subcutaneous administration compatible with ambulatory use
Efficacy	Superiority over placebo on SRI-4 / low disease activity (SLEDAI-2K ≤ 4) at Week 52 with dose-ordered response	Statistically significant, clinically meaningful superiority on the primary endpoint
Pharmacodynamics	Near-complete peripheral CD19+ B-cell depletion with serological normalisation (anti-dsDNA, C3/C4)	Demonstrable, durable target engagement linked to response
Safety	Manageable, monitorable class risks with no new toxicity beyond the B-cell–depletion mechanism	Acceptable benefit–risk over the induction period, characterised risks addressed by labelling and pharmacovigilance
Immunogenicity	Low incidence of anti-drug antibodies (ADA) with no clinically relevant impact on exposure, efficacy, or safety	ADA characterised and without a benefit–risk–altering effect
Regulatory	BLA approval under 21 CFR Part 601; aligned multi-regional filings	Approvable US application supported by one adequate and well-controlled confirmatory study plus supportive data

3. Disease Background and Unmet Medical Need

SLE is a chronic, relapsing–remitting, multisystem autoimmune disease driven by loss of tolerance to nuclear self-antigens, production of pathogenic autoantibodies (notably anti–double-stranded DNA [anti-dsDNA]), immune-complex deposition, and complement consumption. Manifestations span skin, joints, serosal surfaces, haematological lineages, and kidney. Patients with moderate-to-severe active disease frequently remain inadequately controlled despite glucocorticoids, antimalarials (e.g., hydroxychloroquine), and conventional immunosuppressants, and they accrue irreversible organ damage compounded by cumulative glucocorticoid toxicity. B lymphocytes are central to pathogenesis as precursors of autoantibody-secreting cells, as antigen-presenting cells, and as producers of pro-inflammatory cytokines. Depletion of the autoreactive B-cell compartment is therefore a mechanistically rational strategy and is the basis for the OBX-319 programme. The unmet need — durable disease control with glucocorticoid sparing and prevention of damage accrual — frames the primary registrational endpoint and the pharmacodynamic (PD) programme.

4. Molecule, Modality, and Mechanism of Action

OBX-319 is a humanized IgG1 bispecific monoclonal antibody that simultaneously engages two B-lineage surface antigens, CD20 and CD19. CD20 is expressed from the pre-B stage through mature and memory B cells but is largely absent on plasmablasts and plasma cells; CD19 has a broader expression window that begins earlier in the B lineage and persists on plasmablasts and a subset of short-lived plasma cells. Co-targeting both antigens is designed to achieve deeper and broader depletion of the pathogenic B-cell pool than single-antigen (anti-CD20 alone) approaches, including populations that may partially escape CD20-directed therapy. Depletion is mediated through the intact human IgG1 Fc via antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). The subcutaneous route supports outpatient administration and underpins the ambulatory positioning in the TPP.

Because OBX-319 is a bispecific IgG1, the development strategy explicitly addresses molecular-format attributes that do not arise for conventional monoclonal antibodies: correct chain pairing and quantitation of mispaired/half-antibody species, bivalent versus monovalent target engagement, and the effector-function consequences of Fc glycosylation. These attributes are carried consistently across the quality, nonclinical, and clinical pharmacology work streams.

5. Quality / CMC Development Strategy

OBX-319 drug substance is produced by recombinant expression in a CHO cell line and purified using a platform downstream process comprising Protein A affinity capture followed by orthogonal polishing chromatography and dedicated viral-clearance steps. The control strategy targets attributes characteristic of a bispecific IgG1 — correct chain pairing and mispaired/half-antibody content, charge variants, aggregate/high-molecular-weight species, and Fc glycosylation (relevant to effector function and clearance) — with method development and validation supporting each critical quality attribute.

The quality programme is developed consistent with the applicable ICH guidance for a biotechnology-derived product: ICH Q6B (specifications, test procedures, and acceptance criteria for biotechnological/biological products), ICH Q5C (stability of biotechnological/biological products), and ICH Q5A(R2) (viral safety evaluation of biotechnology products derived from cell lines of human or animal origin). Comparability across process and scale changes is managed under ICH Q5E. CMC deliverables — drug substance and drug product manufacture, control strategy, process validation, analytical method validation, stability, and the container-closure/subcutaneous presentation — are sequenced to be at commercial-readiness for the BLA and are detailed in Module 3 with the Quality Overall Summary in Module 2.3. CMC readiness is a gating item on the critical path to submission.

6. Nonclinical Development Strategy

The CD19 and CD20 epitopes engaged by OBX-319 are not conserved in rodents; there is no pharmacological cross-reactivity in rodent species, and the cynomolgus monkey is the sole pharmacologically relevant species. The nonclinical programme was therefore designed in accordance with ICH S6(R1) (preclinical safety evaluation of biotechnology-derived pharmaceuticals) and comprised in-vitro binding and effector-function characterisation, tissue cross-reactivity, PK/PD evaluation, and repeat-dose toxicology in the cynomolgus monkey. The principal findings were the anticipated on-target consequences of B-cell depletion and associated pharmacological immunomodulation, with recovery on cessation of dosing.

Consistent with ICH S6(R1) and the monoclonal-antibody modality, genotoxicity, carcinogenicity, hERG/in-vitro cardiac ion-channel assays, and a dedicated thorough-QT study were not conducted, as they are not warranted for a large, target-specific protein therapeutic that does not distribute to the nucleus, is not expected to interact directly with cardiac ion channels, and is catabolised to endogenous amino acids. This scoping decision is documented in the nonclinical overview (Module 2.4) and is a point of alignment sought at health-authority interactions to avoid unnecessary studies.

7. Clinical Pharmacology Strategy

The pharmacokinetics of OBX-319 are governed by target-mediated drug disposition (TMDD): at low concentrations, binding to and internalisation by CD19/CD20-bearing B cells contribute a saturable, nonlinear elimination pathway, which gives way to approximately linear (predominantly catabolic) clearance once target is saturated and the peripheral B-cell compartment is depleted. The clinical pharmacology package characterises subcutaneous absorption and bioavailability, exposure–response for both efficacy and the depletion PD marker, and the relationship between exposure and the class safety risks. Population PK and exposure–response modelling integrate data across the early-phase studies to justify the two active regimens (High-dose and Low-dose) carried into the confirmatory study.

As an exogenous therapeutic protein, OBX-319 carries an inherent potential for immunogenicity. ADA, including neutralising antibodies, are evaluated with a tiered (screening/confirmatory/titre/neutralising) assay strategy, with assessment of any impact on exposure, PD, efficacy, and safety. Immunogenicity is treated as a cross-cutting risk that informs dose, regimen, and monitoring, and its results are reconciled with the PK and safety databases. Because a mAb of this class does not warrant a thorough-QT evaluation, cardiac-repolarisation characterisation is addressed through the standard safety database rather than a dedicated QT study.

8. Overall Clinical Development Programme

The clinical programme follows a conventional phase progression tailored to a B-cell–depleting biologic, moving from first-in-human safety and PK/PD through dose-ranging to a single adequate and well-controlled confirmatory trial.

Phase	Objective	Role in the package
Phase 1 (single-ascending dose)	First-in-human safety, tolerability, PK, and initial depletion PD; subcutaneous administration	Establishes the exposure range and confirms target engagement
Phase 1 (multiple-ascending dose)	Repeat-dose safety, PK linearity/TMDD, durability of B-cell depletion, ADA	Informs feasible regimens and monitoring
Phase 2 (dose-ranging)	Efficacy signal and exposure–response across candidate regimens in active SLE	Selects the High-dose and Low-dose regimens for confirmation
Phase 3 (confirmatory)	Confirm efficacy and characterise safety versus placebo on background standard of care	Pivotal evidence for the BLA (OBX319-301)

The two active regimens taken into Phase 3 (High-dose and Low-dose) were selected from the integrated early-phase PK/PD and exposure–response analysis, with the dose-ranging results providing the bridge from PD-defined depletion to clinical benefit.

9. Pivotal Study OBX319-301 — Design and Role

OBX319-301 is the confirmatory trial that establishes efficacy and characterises safety for registration. It is a Phase 3, randomized, double-blind, placebo-controlled study in which 480 subjects with moderate-to-severe active SLE on background standard of care were randomized 1:1:1 to OBX-319 High-dose (162), OBX-319 Low-dose (158), or placebo (160) and treated for 52 weeks. The population had active disease at entry, with a mean baseline SLEDAI-2K of approximately 11, consistent with the target indication. Randomization was stratified to balance baseline disease activity and background therapy, and the double-blind design with matched subcutaneous placebo preserved masking across arms. The primary endpoint is SRI-4 response at Week 52, operationalised as low disease activity (SLEDAI-2K ≤ 4); the key secondary endpoint is the change from baseline in SLEDAI-2K. The inclusion of two active regimens supports a dose-ordered efficacy read and strengthens the internal consistency of the evidence. This single confirmatory study, together with the supportive clinical pharmacology, nonclinical, and quality packages, constitutes the primary evidentiary basis for the marketing application.

10. Efficacy Evidence

Both active regimens produced statistically significant and clinically meaningful improvements over placebo, with a consistent dose-ordered effect (High-dose > Low-dose > placebo).

Key secondary — SLEDAI-2K change from baseline at Week 52 (ANCOVA)

Arm	N	LS-mean Δ SLEDAI-2K @ Wk 52 (points)	Diff vs placebo (95% CI)	p
OBX-319 High	162	-6.37	-2.91 (-3.12, -2.69)	0.0000
OBX-319 Low	158	-5.62	-2.17 (-2.38, -1.95)	0.0000
Placebo	160	-3.46	— (reference)	—

Primary — Low disease activity (SLEDAI-2K ≤ 4) at Week 52

Arm	N	Responders, n/N	Rate	Risk diff vs placebo (95% CI, %)	p
OBX-319 High	145	76/145	52.4%	46.4% (37.4, 55.4)	0.0000
OBX-319 Low	145	49/145	33.8%	27.8% (19.2, 36.4)	0.0000
Placebo	150	9/150	6.0%	— (reference)	—

The magnitude of the placebo-adjusted responder difference (46.4 percentage points for High-dose; 27.8 percentage points for Low-dose) is large relative to the modest placebo response (6.0%) typical of an active-disease SLE population on background therapy. The clinical effect is mechanistically corroborated by the PD data: on the active arms, OBX-319 produced near-complete depletion of circulating CD19+ B cells (from approximately 210 to approximately 7 cells/µL), whereas B-cell counts were essentially unchanged in the placebo arm. Depletion was accompanied by falling anti-dsDNA titres and normalisation of complement components C3 and C4 in association with clinical response, providing biologically coherent, target-engagement-linked support for the primary and key secondary findings.

11. Safety Strategy and Risk Management

The safety strategy is built around the anticipated consequences of the mechanism of action. Serious and opportunistic infections and hypogammaglobulinaemia are the key identified risks of profound B-cell depletion; they are managed through immunoglobulin monitoring, infection surveillance, and appropriate screening (including for latent infection) prior to and during therapy, and are reflected in labelling and the pharmacovigilance plan. As a subcutaneously administered therapeutic protein, OBX-319 is associated with expected injection-site/administration reactions and with the potential for immunogenicity, both of which are monitored throughout. Risks associated with unrelated pharmacological classes are not applicable to this modality; in particular, no thyroid-related boxed warning is relevant, as C-cell/thyroid effects belong to a different drug class and are not part of the OBX-319 safety characterisation.

The Week 52 double-blind safety summary showed an adverse-event burden broadly comparable across arms.

Arm	N	≥1 TEAE	SAE	Deaths	Discontinued
OBX-319 High	162	78	2	1	17
OBX-319 Low	158	74	1	0	13
Placebo	160	78	1	0	10

Most frequent adverse events (subjects, by arm)

Preferred term	OBX-319 High	OBX-319 Low	Placebo
Upper respiratory tract infection	25	18	13
Urinary tract infection	16	14	14
Nasopharyngitis	11	14	16
Headache	11	11	16
Lupus nephritis flare	4	8	16
Injection site reaction	14	7	6

Infections (predominantly upper respiratory tract and urinary tract) were among the most frequent events, with a modest dose-related increase in upper respiratory tract infection on the High-dose arm; most were non-serious and manageable. Serious adverse event counts were low and comparable across arms (High-dose 2, Low-dose 1, placebo 1), and the single death occurred on the High-dose arm. Injection-related reactions (Injection site reaction: High-dose 14, Low-dose 7, placebo 6) were generally mild-to-moderate and self-limited, with no new hypersensitivity signal beyond expectations for the class. Lupus nephritis flare was reported least often on the High-dose arm (4) and most often on placebo (16), directionally consistent with disease control by active treatment rather than a treatment-emergent toxicity. The identified and potential risks feed directly into the Risk Management Plan and the pharmacovigilance strategy.

12. Statistical and Estimand Framework

The primary comparison contrasts each active regimen against placebo on background standard of care over the 52-week randomized period. The continuous SLEDAI-2K change from baseline is analysed by ANCOVA with treatment and baseline SLEDAI-2K as covariates, yielding least-squares (LS) mean changes and treatment differences with 95% confidence intervals. The binary low-disease-activity (SLEDAI-2K ≤ 4) responder endpoint is analysed as the proportion of responders at Week 52, with subjects who discontinued randomized treatment or lacked an evaluable Week 52 assessment handled as non-responders; risk differences versus placebo are presented with 95% confidence intervals. Type I error across the primary and key secondary endpoints is controlled by a pre-specified hierarchical testing procedure. The estimand, intercurrent-event handling, and sensitivity analyses are specified in the Statistical Analysis Plan (SAP-301) and reported in the Statistical Analysis Report (SAR-301), ensuring the confirmatory claim rests on a pre-defined analysis.

13. Regulatory Strategy and Health Authority Interactions

OBX-319 is regulated as a biological product; the marketing application is submitted as a Biologics License Application (BLA) under 21 CFR Part 601, in eCTD format under ICH M4/M4E(R2). The interaction plan is sequenced to de-risk the confirmatory study and to align on the modality-specific scoping decisions (single relevant tox species; omission of genotoxicity, carcinogenicity, hERG, and thorough-QT studies) ahead of submission.

Interaction	Purpose	Programme point
Pre-IND meeting	Align on nonclinical package (ICH S6(R1), cynomolgus-only), first-in-human design, and immunogenicity strategy	Before IND
End-of-Phase 2 (EOP2) meeting	Confirm confirmatory design, endpoints, estimand, dose selection (High-dose/Low-dose), and safety database	Before Phase 3 start
Pre-BLA / Pre-NDA meeting	Agree BLA content, integrated summaries, and format; confirm CMC and pharmacovigilance readiness	Before submission
Expedited-programme requests	Seek Fast Track/Breakthrough/Priority Review and EU PRIME/accelerated assessment where the unmet-need and effect-size data support	As data mature

Health-authority interactions are supported by the corresponding briefing books (Pre-IND, EOP2, Pre-NDA) and the expedited-programme request evaluation. The programme is planned as a multi-regional filing: a US BLA under 21 CFR Part 601, an EU marketing-authorisation application with the Summary of Product Characteristics and EU Risk Management Plan, and a regional MFDS submission, each supported by the shared Module 2–5 content and region-specific Module 1. Consistency of the efficacy and safety datasets across regions is maintained by the single confirmatory study and the integrated summaries of efficacy and safety.

14. Paediatric and Lifecycle Development

Paediatric development is addressed through an initial US paediatric study plan (iPSP) and an EU Paediatric Investigation Plan under Regulation (EC) No 1901/2006, including age-appropriate formulation considerations and, where justified, requests for waiver or deferral. Lifecycle development considers additional SLE populations and manifestations (including organ-specific disease), regimen and presentation optimisation for the subcutaneous route, and evidence generation to support maintenance/durability claims. These work streams are planned but are outside the initial registrational package and do not gate the first BLA.

15. Pharmacovigilance and Post-Marketing Commitments

The pharmacovigilance strategy is proportionate to the identified and potential risks of therapeutic B-cell depletion. Routine pharmacovigilance is supplemented by targeted activities for serious/opportunistic infection, hypogammaglobulinaemia, injection/administration reactions, and immunogenicity, with risk minimisation reflected in labelling (screening, immunoglobulin and infection monitoring). The Risk Management Plan (EU) and the corresponding US and regional risk-management documentation, together with periodic benefit–risk evaluation reporting and a signal-management plan, define post-authorisation surveillance. Any post-marketing study commitments arising from health-authority interactions are tracked against the CDP and the programme milestones.

16. Path to Registration — Milestones and Submission Plan

The critical path to registration runs through completion and reporting of OBX319-301, finalisation of the integrated summaries of efficacy and safety, CMC commercial-readiness (process validation, method validation, stability under ICH Q5C), and the pre-submission health-authority alignment.

Milestone	Gating deliverable
Pre-IND alignment	Agreed nonclinical/first-in-human strategy
IND open / first-in-human	Cleared IND; SAD/MAD initiated
Dose selection	Integrated PK/PD and exposure–response; High-dose/Low-dose confirmed
EOP2 alignment	Confirmatory design and endpoints agreed
Confirmatory readout	OBX319-301 database lock and Clinical Study Report (CSR-301)
Integrated summaries	ISE/ISS finalised; benefit–risk assembled
CMC readiness	Process/method validation and stability supportive of commercial supply
Pre-BLA alignment	Agreed application content and format
BLA submission	eCTD application under 21 CFR Part 601

17. Key Assumptions, Risks, and Success Criteria

The plan assumes that the confirmatory efficacy result is replicated in the integrated analysis, that the safety profile remains consistent with the characterised class risks, that immunogenicity does not materially alter exposure or benefit–risk, and that CMC deliverables reach commercial-readiness on the critical path. The principal programme risks — clinical (durability and infection burden), nonclinical (reliance on a single pharmacologically relevant species), CMC (bispecific chain-pairing control and comparability), and regulatory (acceptance of a single confirmatory study and the scoping of omitted nonclinical studies) — are tracked in the Program Risk Register (PM-004) with owners and mitigations.

Success is defined against the TPP: statistically significant, clinically meaningful, dose-ordered superiority over placebo on the primary low-disease-activity endpoint at Week 52 (achieved: 52.4% High, 33.8% Low, 6.0% placebo), corroborated by near-complete CD19+ B-cell depletion (approximately 210 to approximately 7 cells/µL) and serological normalisation, against a manageable and monitorable safety profile consistent with the B-cell–depletion mechanism. On the totality of the efficacy, pharmacodynamic, and safety evidence, the benefit–risk balance supports progression to a marketing application, and the programme is directed to a BLA under 21 CFR Part 601 with aligned multi-regional filings.